Lamdong Pharmaceutical JSC (HNX:LDP)
Vietnam
· Delayed Price · Currency is VND 8,500.00
-200.00 (-2.30%)
At close: Mar 6, 2026
HNX:LDP Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 243,906 | 217,958 | 186,001 | 187,415 | 161,902 | Upgrade
|
| Revenue Growth (YoY) | 11.91% | 17.18% | -0.75% | 15.76% | -57.36% | Upgrade
|
| Cost of Revenue | 162,674 | 153,567 | 148,835 | 149,895 | 140,678 | Upgrade
|
| Gross Profit | 81,232 | 64,390 | 37,166 | 37,519 | 21,225 | Upgrade
|
| Selling, General & Admin | 65,072 | 51,110 | 49,512 | 62,833 | 41,013 | Upgrade
|
| Operating Expenses | 65,072 | 51,110 | 49,512 | 62,833 | 41,013 | Upgrade
|
| Operating Income | 16,160 | 13,280 | -12,347 | -25,314 | -19,788 | Upgrade
|
| Interest Expense | -4,160 | -4,979 | -7,027 | -7,544 | -2,210 | Upgrade
|
| Interest & Investment Income | 999.28 | 281.55 | 775.36 | 2,862 | 31,615 | Upgrade
|
| Other Non Operating Income (Expenses) | 14,401 | -299.96 | 21.67 | -8,851 | 31,105 | Upgrade
|
| EBT Excluding Unusual Items | 27,400 | 8,283 | -18,576 | -38,848 | 40,721 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -1,428 | -634.63 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 63.64 | -894.01 | - | - | Upgrade
|
| Pretax Income | 27,400 | 6,919 | -20,105 | -38,848 | 40,721 | Upgrade
|
| Income Tax Expense | - | - | - | 43.69 | 2,850 | Upgrade
|
| Net Income | 27,400 | 6,919 | -20,105 | -38,891 | 37,870 | Upgrade
|
| Net Income to Common | 27,400 | 6,919 | -20,105 | -38,891 | 37,870 | Upgrade
|
| Net Income Growth | 296.02% | - | - | - | 295.07% | Upgrade
|
| Shares Outstanding (Basic) | 19 | 13 | 13 | 13 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 19 | 13 | 13 | 13 | 13 | Upgrade
|
| Shares Change (YoY) | 47.44% | - | 0.01% | -0.02% | 62.22% | Upgrade
|
| EPS (Basic) | 1463.00 | 544.66 | -1582.67 | -3062.00 | 2981.00 | Upgrade
|
| EPS (Diluted) | 1463.00 | 544.66 | -1583.00 | -3062.00 | 2981.00 | Upgrade
|
| EPS Growth | 168.61% | - | - | - | 143.55% | Upgrade
|
| Free Cash Flow | -60,572 | 5,835 | 5,977 | -46,718 | 21,392 | Upgrade
|
| Free Cash Flow Per Share | -3234.13 | 459.36 | 470.51 | -3678.26 | 1683.88 | Upgrade
|
| Gross Margin | 33.30% | 29.54% | 19.98% | 20.02% | 13.11% | Upgrade
|
| Operating Margin | 6.63% | 6.09% | -6.64% | -13.51% | -12.22% | Upgrade
|
| Profit Margin | 11.23% | 3.17% | -10.81% | -20.75% | 23.39% | Upgrade
|
| Free Cash Flow Margin | -24.83% | 2.68% | 3.21% | -24.93% | 13.21% | Upgrade
|
| EBITDA | 21,735 | 20,093 | -4,110 | -16,414 | -8,047 | Upgrade
|
| EBITDA Margin | 8.91% | 9.22% | -2.21% | -8.76% | -4.97% | Upgrade
|
| D&A For EBITDA | 5,575 | 6,813 | 8,237 | 8,900 | 11,742 | Upgrade
|
| EBIT | 16,160 | 13,280 | -12,347 | -25,314 | -19,788 | Upgrade
|
| EBIT Margin | 6.63% | 6.09% | -6.64% | -13.51% | -12.22% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 7.00% | Upgrade
|
| Revenue as Reported | 243,906 | 217,958 | 186,001 | 187,415 | 161,902 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.